Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.
(SUSTAIN 7 Trial)
Recruiting in Palo Alto (17 mi)
+178 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Waitlist Available
Sponsor: Novo Nordisk A/S
No Placebo Group
Pivotal Trial (Near Approval)
Prior Safety Data
Trial Summary
What is the purpose of this trial?
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes.
Eligibility Criteria
Inclusion Criteria
Inclusion Criteria: - Male or female, age at least 18 years at the time of signing informed consent. - HbA1c (glycosylated haemoglobin) 7.0 - 10.5% (53 - 91 mmol/mol) (both inclusive) - Subjects on stable diabetes treatment with metformin (minimum of 1500 mg/day or maximal tolerated dose documented in the patient medical record) for 90 days prior to screening
Treatment Details
Interventions
- Dulaglutide (Glucagon-like peptide-1 receptor agonist)
- Semaglutide (Glucagon-like peptide-1 receptor agonist)
Participant Groups
4Treatment groups
Experimental Treatment
Active Control
Group I: Semaglutide 1.0 mg/WeekExperimental Treatment1 Intervention
Group II: Semaglutide 0.5 mg/WeekExperimental Treatment1 Intervention
Group III: Dulaglutide 0.75 mg/WeekActive Control1 Intervention
Group IV: Dulaglutide 1.5 mg/WeekActive Control1 Intervention
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Novo Nordisk Investigational SiteDenver, CO
Novo Nordisk Investigational SiteEdgewater, FL
Novo Nordisk Investigational SiteFort Lauderdale, FL
Novo Nordisk Investigational SitePoway, CA
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Novo Nordisk A/SLead Sponsor